Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
Study shows potential of treating recurrent CDI with frozen fecal matter

Study shows potential of treating recurrent CDI with frozen fecal matter

A preliminary study has shown the potential of treating recurrent Clostridium difficile infection (a bacterium that is one of the most common causes of infection of the colon) with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent, according to a study published in JAMA. [More]
RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis. [More]
Study finds that hospitalized patients wash their hands infrequently

Study finds that hospitalized patients wash their hands infrequently

Hospital visitors and staff are greeted with hand sanitizer dispensers in the lobby, by the elevators and outside rooms as reminders to wash their hands to stop infections, but just how clean are patients' hands? [More]
TRU-D SmartUVC’s Ebola-killing UVC automated disinfection robot to be showcased at IDWeek 2014

TRU-D SmartUVC’s Ebola-killing UVC automated disinfection robot to be showcased at IDWeek 2014

TRU-D SmartUVC LLC will feature its Ebola-killing UVC automated disinfection robot at IDWeek 2014 in Philadelphia this week from October 8 to 12 at booth 826. [More]
Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. [More]
Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

The transplantation of faecal microbiota from a healthy donor has been shown in recent clinical studies to be a safe and highly effective treatment for recurrent Clostridium difficile (C. difficile) infection and is now recommended in European treatment guidelines. [More]
C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

C Diff Foundation is proud to present the 2014 "Raising C.difficile Awareness" conference. Join us November 4th at 8 a.m. – 5 p.m. at the University of Illinois at Chicago, Student Center, West 828 S. Wolcott Avenue, Thompson Room, Chicago, IL. [More]
Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. [More]
Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs. [More]
Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs, which promote the appropriate use of antibiotics in hospitals and other healthcare centers, not only lead to reduction in antibiotic use with reduced adverse events, but also lead to significant savings. [More]
Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. [More]
University of Leicester research sniffs out smell of disease in feces

University of Leicester research sniffs out smell of disease in feces

A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria C. diff, that causes diarrhoea, temperature and stomach cramps, has been developed by a team at the University of Leicester. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Kaiser Permanente and Johns Hopkins Medicine today announced plans to strengthen the successful collaboration between the two health care organizations. [More]
Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance released today offers updated evidence reviews and recommendations for hand hygiene in healthcare facilities. [More]
NIAID launches CRS3123 Phase I trial to treat C. difficile infection

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. [More]
Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative. [More]

Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Among patients who underwent gall bladder removal for acute calculous cholecystitis, lack of postoperative antibiotic treatment did not result in a greater incidence of infections, according to a study in the July 9 issue of JAMA. [More]